2026 Global: Biopharmaceutical Contract Manufacturing Market -Competitive Review (2032) report
Description
The 2026 Global: Biopharmaceutical Contract Manufacturing Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biopharmaceutical contract manufacturing market by geography and historical trend. The scope of the report extends to sizing of the biopharmaceutical contract manufacturing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Lonza, Thermo Fisher Scientific (Patheon), Catalent, Samsung Biologics, WuXi Biologics (WuXi AppTec), Fujifilm Biotechnologies (FUJIFILM Diosynth/Fujifilm Life Sciences), Boehringer Ingelheim (BioXcellence), Recipharm, Siegfried, and MilliporeSigma/Merck KGaA are widely recognized as ten major companies shaping the biopharmaceutical contract manufacturing market.
Lonza is a global CDMO leader offering integrated development-to-commercialization services across biologics, cell and gene therapies, and small molecules; its modular manufacturing platforms and emphasis on sustainability and scalable commercial supply make it a frequent first choice for complex biologics programs. Thermo Fisher Scientific, through its Patheon and broad life‑science portfolio, provides end‑to‑end CDMO services for small and large molecules, with major investments in purification, sterile manufacturing, and cell and gene therapy capabilities that strengthen its global footprint and regulatory compliance offerings. Catalent differentiates with advanced drug‑delivery and formulation expertise plus extensive fill/finish capacity, backing fast transitions from development to launch for biologics and advanced therapies while investing in digital analytics and quality‑by‑design processes. Samsung Biologics supplies large‑scale, vertically integrated biomanufacturing capacity especially suited for monoclonal antibodies and recombinant proteins, leveraging state‑of‑the‑art facilities in South Korea and competitive commercial throughput for global partners. WuXi Biologics (WuXi AppTec) combines broad biologics process development with multiple GMP facilities and recently demonstrated regulatory readiness across drug substance and drug product sites, making it a major Asia‑based CDMO for both clinical and commercial volumes.
Fujifilm Biotechnologies (formerly FUJIFILM Diosynth) has rapidly expanded biologics capacity in the U.S. and globally, securing long‑term commercial agreements and adopting automation and data‑driven quality monitoring to support high‑volume biomanufacturing. Boehringer Ingelheim’s BioXcellence division brings deep biologics process know‑how—cell culture, microbial fermentation, and fill‑finish—supported by strong regulatory systems and investments in automation and sustainability that position it as a trusted partner for complex biologics production. Recipharm, a European CDMO, focuses on flexible development and manufacturing across oral solids, sterile injectables, and biologics/ATMPs, reinforcing its role through strategic portfolio realignment and facility investments. Siegfried (Siegfried Holding AG) provides API and drug‑product CDMO services with capabilities spanning chemical synthesis to finished‑product packaging, serving customers that require integrated supply reliability and compliance. MilliporeSigma (Merck KGaA’s life‑science services) combines CDMO, purification, and analytical services with broad life‑science supply chain integration, offering clients access to upstream/downstream technologies and testing services within a large multinational framework.
Across these ten firms, common strengths are diversified modality coverage (biologics, cell and gene therapies, small molecules), global multi‑site capacity, heavy capital investment in sterile and purification technologies, and emphasis on regulatory readiness and digitalization—factors driving CDMO selection for both emerging biotech and large pharmaceutical sponsors.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biopharmaceutical contract manufacturing market by geography and historical trend. The scope of the report extends to sizing of the biopharmaceutical contract manufacturing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Lonza, Thermo Fisher Scientific (Patheon), Catalent, Samsung Biologics, WuXi Biologics (WuXi AppTec), Fujifilm Biotechnologies (FUJIFILM Diosynth/Fujifilm Life Sciences), Boehringer Ingelheim (BioXcellence), Recipharm, Siegfried, and MilliporeSigma/Merck KGaA are widely recognized as ten major companies shaping the biopharmaceutical contract manufacturing market.
Lonza is a global CDMO leader offering integrated development-to-commercialization services across biologics, cell and gene therapies, and small molecules; its modular manufacturing platforms and emphasis on sustainability and scalable commercial supply make it a frequent first choice for complex biologics programs. Thermo Fisher Scientific, through its Patheon and broad life‑science portfolio, provides end‑to‑end CDMO services for small and large molecules, with major investments in purification, sterile manufacturing, and cell and gene therapy capabilities that strengthen its global footprint and regulatory compliance offerings. Catalent differentiates with advanced drug‑delivery and formulation expertise plus extensive fill/finish capacity, backing fast transitions from development to launch for biologics and advanced therapies while investing in digital analytics and quality‑by‑design processes. Samsung Biologics supplies large‑scale, vertically integrated biomanufacturing capacity especially suited for monoclonal antibodies and recombinant proteins, leveraging state‑of‑the‑art facilities in South Korea and competitive commercial throughput for global partners. WuXi Biologics (WuXi AppTec) combines broad biologics process development with multiple GMP facilities and recently demonstrated regulatory readiness across drug substance and drug product sites, making it a major Asia‑based CDMO for both clinical and commercial volumes.
Fujifilm Biotechnologies (formerly FUJIFILM Diosynth) has rapidly expanded biologics capacity in the U.S. and globally, securing long‑term commercial agreements and adopting automation and data‑driven quality monitoring to support high‑volume biomanufacturing. Boehringer Ingelheim’s BioXcellence division brings deep biologics process know‑how—cell culture, microbial fermentation, and fill‑finish—supported by strong regulatory systems and investments in automation and sustainability that position it as a trusted partner for complex biologics production. Recipharm, a European CDMO, focuses on flexible development and manufacturing across oral solids, sterile injectables, and biologics/ATMPs, reinforcing its role through strategic portfolio realignment and facility investments. Siegfried (Siegfried Holding AG) provides API and drug‑product CDMO services with capabilities spanning chemical synthesis to finished‑product packaging, serving customers that require integrated supply reliability and compliance. MilliporeSigma (Merck KGaA’s life‑science services) combines CDMO, purification, and analytical services with broad life‑science supply chain integration, offering clients access to upstream/downstream technologies and testing services within a large multinational framework.
Across these ten firms, common strengths are diversified modality coverage (biologics, cell and gene therapies, small molecules), global multi‑site capacity, heavy capital investment in sterile and purification technologies, and emphasis on regulatory readiness and digitalization—factors driving CDMO selection for both emerging biotech and large pharmaceutical sponsors.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.